Company Overview of Cerecor Inc.
Cerecor, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs for the treatment of patients with neurological and psychiatric disorders. The company has a portfolio of clinical and preclinical compounds, such as CERC-301, CERC-501, and CERC-406. It develops CERC-301 that is in Phase II development stage as an oral, adjunctive antidepressant for the treatment of patients with major depressive disorder (MDD); CERC-501, which is in Phase II development, for co-occurring psychiatric and substance use disorders; and CERC-406 that is its preclinical lead candidate that inhibit catechol-O-methyltransferase within the brain, as well as anticipates developing CERC-406...
400 East Pratt Street
Baltimore, MD 21202
Founded in 2011
Key Executives for Cerecor Inc.
Chief Business Officer
Total Annual Compensation: $407.2K
Total Annual Compensation: $589.1K
Compensation as of Fiscal Year 2014.
Cerecor Inc. Key Developments
Cerecor Inc. Announces Enrollment of First Subject in the Phase 2 Clinical Trial for CERC-501
Feb 2 16
On February 2, 2016, Cerecor Inc. announced that it had enrolled its first subject in the Phase 2 clinical trial for CERC-501, A Randomized, Double-Blind, Placebo-Controlled, Cross-over Design Study of CERC-501 in a Human Laboratory Model of Smoking Behavior. The study is a thirty-day, double-blind, placebo-controlled, crossover study in subjects who are heavy cigarette smokers and currently not seeking treatment for tobacco use disorder, and the trial design assumes enrollment of 66 subjects. Massachusetts General Hospital CERC-501 Phase 2 Clinical Trial for Treatment-Resistant Depression: The National Institutes of Health (NIH) discontinued the National Institute of Mental Health-funded Phase 2 clinical trial for CERC-501, Double-Blind, Placebo Controlled, Proof-of-Concept Trial of LY2456302, a Kappa Selective Opioid Receptor Antagonist, and Augmentation of Antidepressant Therapy in Treatment-Resistant Depression, which was sponsored by Massachusetts General Hospital. The company has been advised that the reason for the discontinuation is slow study progression.
Cerecor Inc. Appoints Thomas H. Aasen as Director and Member of the Audit Committee
Jan 12 16
On January 10, 2016, Cerecor Inc. appointed Thomas H. Aasen to the Board. Mr. Aasen will serve as a Class III director and will also serve as a member of the audit committee of the Board. Mr. Aasen served in various roles at Acadia Pharmaceuticals Inc. from 1998 to 2014, most recently as the Executive Vice President, Chief Financial Officer and Chief Business Officer. Previously, Mr. Aasen held financial management positions at three other life sciences companies, including Axys Pharmaceuticals, formerly Sequana Therapeutics, Genta Inc., and Gen-Probe Inc.
Cerecor Inc. Announces Management Changes
Dec 21 15
Cerecor Inc. announced that Uli Hacksell has been named to the additional positions of CEO and President as of January 1, 2016. Dr. Blake Paterson will step down as the company’s CEO and resign from its board, but will continue to work with the company as a scientific advisor. Dr. Hacksell joined Cerecor Inc. in May 2015 as its Chairman, seeing the company through its initial public offering. Prior to Cerecor, Dr. Hacksell served as Chief Executive Officer of ACADIA from September 2000 to March 2015 and was a member of its Board of Directors.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|